Opiates and opioid peptides act by binding to specific receptor binding sites which are coupled to second messenger systems in neuronal cell membranes. One such second messenger system is opiate-mediated inhibition of adenylate cyclase, in which receptors are coupled to adenylate cyclase through specific auanine nucleotide binding proteins. This activity can now be measured reproducibly in brain membranes by a technique of low pH pretreatment which selectively eliminates stimulation of adenylate cyclase by other receptors but increases inhibition of adenylate cyclase by opiate agonists. This technique also increases the regulation of opite agonist binding sites by guanine nucleotides. This project will study the molecular mechanisms in brain membranes that regulate the coupling of opiate receptor to adenylate cyclase. First, it will explore the pharmacological properties of opiate-inhibited adenylate cyclase and determine the nature of the opiate receptor subtypes involved in this second messenger system. Second, this research will study the biochemical factors which regulate the activity of this system: by labeling the guanine nucleotide binding proteiins in brain membranes, it will determine the nature of the low pH effect which alters the balance between stimulated and inhibited adenylate cyclase. Finally, the project will focus on the effects of opiate tolerance on this second messenger system. Opiate tolerane does not appear to involve a loss of opiate receptor binding sites; however, it may involve a loss of coupling between receptors and adenylate cyclase. These studies will examine this possibililty and search for possible biochemical changes in quanine nucleotide binding proteins that may occur in response to tolerane. This research will not only help describe some of the molecular mechanisms of tolerance in brain, but will also help to explain acute actions of opiates by exploring the factors in brain membranes that regulate expression of opiate-inhibited adenylate cyclase.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Research Project (R01)
Project #
5R01DA002904-10
Application #
3207625
Study Section
Special Emphasis Panel (SRCD)
Project Start
1982-09-30
Project End
1993-08-31
Budget Start
1990-09-30
Budget End
1991-08-31
Support Year
10
Fiscal Year
1990
Total Cost
Indirect Cost
Name
Wake Forest University Health Sciences
Department
Type
Schools of Medicine
DUNS #
041418799
City
Winston-Salem
State
NC
Country
United States
Zip Code
27106
Milivojevic, Verica; Sinha, Rajita; Morgan, Peter T et al. (2014) Effects of endogenous and exogenous progesterone on emotional intelligence in cocaine-dependent men and women who also abuse alcohol. Hum Psychopharmacol 29:589-98
Maher, Catherine E; Martin, Thomas J; Childers, Steven R (2005) Mechanisms of mu opioid receptor/G-protein desensitization in brain by chronic heroin administration. Life Sci 77:1140-54
Sim-Selley, Laura J; Vogt, Leslie J; Childers, Steven R et al. (2003) Distribution of ORL-1 receptor binding and receptor-activated G-proteins in rat forebrain and their experimental localization in anterior cingulate cortex. Neuropharmacology 45:220-30
Bantel, Carsten; Childers, Steven R; Eisenach, James C (2002) Role of adenosine receptors in spinal G-protein activation after peripheral nerve injury. Anesthesiology 96:1443-9
Daunais, J B; Letchworth, S R; Sim-Selley, L J et al. (2001) Functional and anatomical localization of mu opioid receptors in the striatum, amygdala, and extended amygdala of the nonhuman primate. J Comp Neurol 433:471-85
Maher, C E; Eisenach, J C; Pan, H L et al. (2001) Chronic intrathecal morphine administration produces homologous mu receptor/G-protein desensitization specifically in spinal cord. Brain Res 895:1-8
Vogt, L J; Sim-Selley, L J; Childers, S R et al. (2001) Colocalization of mu-opioid receptors and activated G-proteins in rat cingulate cortex. J Pharmacol Exp Ther 299:840-8
Selley, D E; Cao, C C; Sexton, T et al. (2001) mu Opioid receptor-mediated G-protein activation by heroin metabolites: evidence for greater efficacy of 6-monoacetylmorphine compared with morphine. Biochem Pharmacol 62:447-55
Moore, R J; Xiao, R; Sim-Selley, L J et al. (2000) Agonist-stimulated [35S]GTPgammaS binding in brain modulation by endogenous adenosine. Neuropharmacology 39:282-9
Maher, C E; Selley, D E; Childers, S R (2000) Relationship of mu opioid receptor binding to activation of G-proteins in specific rat brain regions. Biochem Pharmacol 59:1395-401

Showing the most recent 10 out of 37 publications